Elevation Oncology
ELEV

$0.6250

6.09%

Market Cap: $36.9M

About: Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Employees: 29

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 12

29% more funds holding

Funds holding: 63 [Q1] → 81 (+18) [Q2]

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

4.92% more ownership

Funds ownership: 90.49% [Q1] → 95.41% (+4.92%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

38% less capital invested

Capital invested by funds: $226M [Q1] → $140M (-$85.5M) [Q2]

67% less call options, than puts

Call options by funds: $2K | Put options by funds: $6K

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

860%

upside

Avg. target

$6.67

967%

upside

High target

$7

1,020%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target	860%upside $6	Buy Reiterated	7 Aug 2024
JMP Securities Silvan Tuerkcan 34% 1-year accuracy 14 / 41 met price target	1,020%upside $7	Market Outperform Reiterated	15 Jul 2024
JMP Securities Silvan Tuerkcan 34% 1-year accuracy 14 / 41 met price target	1,020%upside $7	Market Outperform Reiterated	28 Jun 2024

See Analyst Rankings

Financial journalist opinion

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BOSTON , Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J.

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +

We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. A take on Easterly Government Properties suggests they offer reliable income similar to Treasury bonds with lower reinvestment risk. Bunge Global is seen as holding potential for market expansion opportunities despite its Q2 decline.

Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +

Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?

The stock of Elevation Oncology Inc. ELEV is trading lower on Tuesday after the company reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, or esophageal cancers.

Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?

Elevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical Results

Elevation Oncology's market valuation is poised to drop 50% due to updates on their Claudin ADC, EO-3021. EO-3021, their main project, showed promising response rates in early-stage studies, but market reaction was catastrophic. Financially, Elevation Oncology has sufficient funds to continue operations into 2026, but future funding for later-stage studies remains uncertain.

Elevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical Results

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON , Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent business achievements.

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

-- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer -- -- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/ hypoesthesia -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON , Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced promising initial data from the dose escalation portion of the ongoing Phase 1 clinical trial of EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction (GEJ), pancreatic or esophageal cancers.

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings -- -- On-track to provide update from ongoing Phase 1 clinical trial evaluating monotherapy EO-3021 by mid-3Q 2024, with additional data in 1H 2025 -- BOSTON , June 27, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Company (Lilly) and GSK, respectively, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab, a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab, a PD-1 inhibitor, in the front-line setting.

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

Elevation Oncology to Present at the Citizens JMP Life Sciences Conference

BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET.

Elevation Oncology to Present at the Citizens JMP Life Sciences Conference

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected mid-Q3 of 2024; Additional data expected 1st half of 2025. HER3-ADC is another ADC being developed in the pipeline for the treatment of patients with HER3-expressning solid tumors; It has been shown that up to 42% of tumors express HER3. Nomination of ADC candidate for HER3-ADC clinical program expected in the 2nd half of 2024.

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements

-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-track to nominate development candidate in 2H 2024 -- -- Raised $44.2 million year-to-date through ATM facility, extending cash runway into 2026 -- BOSTON , May 2, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements. "In recent months, we focused on advancing our growing pipeline of differentiated ADCs, each with broad therapeutic potential, and extending our cash runway into 2026, beyond upcoming milestones for EO-3021 and our HER3-ADC program," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.

Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements

See News Rankings